The senolytic ABT-263 improves cognitive functions in middle-aged male, but not female, atherosclerotic LDLr

Mélanie Lambert, Géraldine Miquel, Louis Villeneuve, Nathalie Thorin-Trescases, Eric Thorin

Faculty of Medicine, Department of Pharmacology and Physiology, University of Montreal, Montreal, Quebec, Canada. [email protected]. · pubmed

Paper

Abstract

Accumulation of cerebral senescent cells may compromise the continuum between vascular and neuronal function, leading to damage and cognitive decline. Elimination of senescent cells might therefore preserve vascular and neuronal functions. To test this hypothesis, we used male and female atherosclerotic LDLr

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that the senolytic ABT-263 improves cognitive functions in middle-aged male atherosclerotic LDLr mice. This research is relevant as it addresses the elimination of senescent cells, which is a potential root cause of aging and cognitive decline, thereby contributing to the understanding of interventions that may enhance longevity.

Author of this paper? Send a correction.